1. The Continuing Evolution of Therapy in First Relapse/Refractory Multiple Myeloma

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Monitoring Patients With Multiple Myeloma

4. Multiple Options at First Relapse

5. Therapy Selection Considerations

6. Recent Phase 3 Trials in R/R MM

7. Alternative Approaches

8. Case #1: Carol

9. Case #1: Next Steps

10. Toxicity Considerations With Newer Agents

11. Case #2: Sally

12. Case #2: Next Steps

13. Possible Treatment Strategies

14. Toxicity Considerations With Newer Agents

15. Key Takeaways

16. Abbreviations

17. Abbreviations (cont)

18. Abbreviations (cont)